Loading resource…

Universitätsklinikum der Technischen Universität München, Germany
Dyslipidaemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a significant modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). The paper addresses the underdiagnosis and undertreatment of dyslipidaemia, especially in high-risk patients. It emphasizes the importance of lifestyle interventions and outlines treatment options including statins, ezetimibe, and novel therapies. The document incorporates the latest recommendations from the 2025 Focused Update of the ESC/EAS guidelines, highlighting the need for individualized treatment approaches.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology

PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology

OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology

CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology

The Athlete’s ECG
Same clinical topic · Cardiology

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology

Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology

Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology

INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology